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Differentiation of Mouse Induced Pluripotent Stem
Cells into a Multipotent Keratinocyte Lineage
Ganna Bilousova1,2, Jiang Chen1,2 and Dennis R. Roop1,2
Recent breakthroughs in the generation of induced pluripotent stem cells (iPSCs) have provided a novel
renewable source of cells with embryonic stem cell-like properties, which may potentially be used for gene
therapy and tissue engineering. Although iPSCs have been differentiated into various cell types, iPSC-derived
keratinocytes have not yet been obtained. In this study, we report the in vitro differentiation of mouse iPSCs
into a keratinocyte lineage through sequential applications of retinoic acid and bone-morphogenetic protein-4
and growth on collagen IV-coated plates. We show that iPSCs can be differentiated into functional keratinocytes
capable of regenerating a fully differentiated epidermis, hair follicles, and sebaceous glands in an in vivo
environment. Keratinocytes derived from iPSCs displayed characteristics similar to those of primary
keratinocytes with respect to gene and protein expression, as well as their ability to differentiate in vitro and
to reconstitute normal skin and its appendages in an in vivo assay. At present, no effective therapeutic
treatments are available for many genetic skin diseases. The development of methods for the efficient
differentiation of iPSCs into a keratinocyte lineage will enable us to determine whether genetically corrected
autologous iPSCs can be used to generate a permanent corrective therapy for these diseases.
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INTRODUCTION
The discovery that both mouse and human somatic cells
could be reprogrammed into an embryonic stem cell
(ESC)-like state by transduction with a combination of repro-
gramming factors (such as Oct3/4, Sox2, Klf4, and c-Myc, or
alternatively Oct3/4, Sox2, Nanog, and Lin28) has had a
dramatic effect on the fields of stem cell biology and
regenerative medicine (Takahashi and Yamanaka, 2006;
Wernig et al., 2007; Yu et al., 2007). The therapeutic
potential of such induced pluripotent stem cells (iPSCs) for
tissue repair and regeneration is enormous. Studies describing
the correction of genetic defects in a humanized sickle cell
anemia mouse model (Hanna et al., 2007) and a Parkinson’s
disease rat model (Wernig et al., 2008) by coupling direct
reprogramming and gene targeting suggest that, in principal,
iPSC technology could be used for the development of
customized cellular therapies to treat human diseases.
Furthermore, the therapeutic use of cells derived from a
patient’s own iPSCs would potentially avoid the complication
of immune rejection, which might occur if cells were derived
from allogeneic ESCs.
Recent progress in generating transgene-free human iPSCs
(Kim et al., 2009; Yu et al., 2009; Zhou and Freed, 2009) has
advanced the potential application of iPSCs closer to the
clinic. In addition, substantial progress has been made in
differentiating iPSCs into various cell types, including
neurons (Dimos et al., 2008), cardiomyocytes (Gai et al.,
2009), adipocytes (Taura et al., 2009), hematopoietic cells
(Hanna et al., 2007), and hepatocytes (Ochiya et al., 2010).
The skin is an ideal tissue to initially apply iPSC-based
therapy: it is readily accessible, easy to monitor, and if an
adverse event should occur, the affected cells could be easily
excised. In addition, essentially all of the most devastating
forms of inherited skin diseases are caused by known
monogenetic defects, which in theory should allow their
correction at the DNA level (Tamai et al., 2009; Uitto, 2009).
Therefore, it is surprising that to date no protocols have been
developed for the differentiation of iPSCs into a keratinocyte
lineage.
In this report, we describe an approach that results in the
efficient differentiation of mouse iPSCs into functional
keratinocytes capable of reconstituting a normal stratified
epidermis, hair follicles, and sebaceous glands when grafted
onto mice. This enabling technology will allow us to assess
the feasibility of using iPSCs for the treatment of inherited
skin disorders, using genetically engineered mouse models
that mimic these diseases (Arin et al., 2001; Cao et al., 2001).
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In addition, our approach provides a starting point to
determine whether human iPSCs can be differentiated into
functional multipotent keratinocyte stem cells.
RESULTS
Generation of iPSCs from mouse fibroblasts
We generated iPSCs from mouse fibroblasts using retroviral
vectors encoding four reprogramming factors (namely
Oct3/4, Sox2, Klf4, and c-Myc) (Takahashi and Yamanaka,
2006). Similar to the observation originally made by Yamana-
ka (in the study by Takahashi and Yamanaka (2006)), our iPSC
clones exhibited an ESC-like morphology (Figure 1a and
Supplementary Figure S1a online) and increased the expres-
sion of endogenous Oct3/4, Sox2, and Nanog, genes normally
expressed in mouse ESCs, as determined by reverse transcrip-
tase-PCR (Supplementary Figure S1b online). The activation
of Nanog expression in our iPSC clones was further confirmed
by immunofluorescence analysis (Supplementary Figure S1c
online). The expression of transgenic factors was significantly
suppressed in iPSCs (Supplementary Figure S1b online), but
was not completely silenced, which is consistent with
observations made by other groups (Takahashi and Yamanaka,
2006; Okita et al., 2007; Yu et al., 2007). The incomplete
silencing of at least the c-Myc retrovirus is further supported by
the continuous expression of green fluorescent protein (GFP)
in parental iPSCs (Supplementary Figure S1a online). GFP is
driven by the murine stem cell virus (MSCV)–IRES–GFP vector
expressing c-Myc. The expression of GFP in iPSCs was used as
a marker to track these cells in an in vivo environment.
The iPSCs that we have generated were capable of forming
teratomas following subcutaneous injection into nude
mice. Tissues from all three germ layers were present in
these tumors as detected by immunofluorescence analysis
(Supplementary Figure S2 online). The markers that we
used to identify cells from each germ layer (keratin (Krt)8/
(Krt18)—ectoderm, cytokeratin Endo-A—endoderm, and
heavy-chain myosin from skeletal muscles—mesoderm)
colocalized with GFP, which is expressed in parental iPSCs.
Differentiation of iPSCs into a keratinocyte lineage
To develop a method for differentiation of iPSCs into
functional keratinocytes, we combined the protocols
developed by Aberdam (in the study by Aberdam et al.
(2008)) and by Palecek (in the study by Metallo et al. (2008)).
The differentiation protocol is described in detail in the
‘‘Materials and Methods’’ section and in Supplementary
Figure S3 online. To follow the differentiation process closely
and to compare it with that previously observed during the
differentiation of human ESCs into keratinocytes (Green et al.,
2003), we examined the sequential expression of markers as
iPSCs were differentiated into a keratinocyte lineage.
We started the analysis from embryoid bodies (EBs)
generated from suspended iPSCs in culture (Figure 1b). The
EBs were pre-treated with retinoic acid, plated onto type IV
collagen (ColIV)-coated plates in the presence of bone-
morphogenetic protein-4, and allowed to attach. We used the
expression of Nanog to confirm the ESC phenotype of the
attached EBs, as this particular transcription factor was not
used for the generation of iPSCs. Once cells migrated from
the EB (3 days post-attachment to a plate), the expression
of Nanog disappeared, and the expression of markers of
commitment to an ectodermal fate, Krt8/Krt18, was observed
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Figure 1. Differentiation of iPSCs into a keratinocyte fate. (a) Fibroblasts
from newborn ICR mice were transduced with retroviruses expressing
reprogramming genes and cultured under ESC conditions until iPSC colonies
appeared under phase-contrast microscopy. (b) iPSCs were able to form
embryoid bodies (EBs). (c, c0, d, d0) Three days after attachment of EBs to a
ColIV-coated plate and in the presence of BMP-4, cells migrated from EBs,
turned off Nanog expression (red), and began expressing Krt8/Krt18 (green)
(c and c0). At this time point, no p63 (red) or Krt14 (green) expression was
observed (d and d0). (e, e0, f, f 0) On day 9 after attachment, the majority of
cells expressed Krt8/Krt18 (e and e0) and p63 (f and f 0), and some of the cells
began expressing (f and f 0) Krt14. Panels c0, d0, e0 and f 0 are high-magnification
views of panels c, d, e and f respectively. The images are representative of
two independent differentiation experiments. BMP-4, bone-morphogenetic
protein-4; ColIV, type IV collagen; ESC, embryonic stem cell; iPSC, induced
pluripotent stem cell; Krt, keratin. Bar¼100mm.
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(Figure 1c and c0). At this time point, cells did not express
p63, a master regulator required for the commitment of the
ectoderm to a keratinocyte fate (Mills et al., 1999; Koster
et al., 2004), nor Krt14, a keratin marker confirming the
commitment of the ectoderm to a keratinocyte fate (Figure 1d
and d0). Later in the differentiation process (9 days post-
attachment), most of the cells that had migrated away from
the EB started expressing p63, and some of the cells located at
the migrating front began to express Krt14 (Figure 1f and f0),
whereas cells that were still located next to the EB exhibited
only an ectodermal fate (expression of Krt8/Krt18 and loss of
expression of Nanog) (Figure 1e and e0). At this point, we
removed the clumps of cells from the nonmigrating part of the
EBs by vacuum aspiration, and the remaining cells were
analyzed for the expression of Krt14 by flow cytometry, which
showed thatB25% of the cells were Krt14 positive (Figure 2c)
as compared to undifferentiated iPSCs (B1%) (Figure 2a).
Krt14-positive epidermal stem cells have previously been
shown to differ from their differentiated progeny by their
ability to rapidly attach to ColIV-coated surfaces (Bickenbach
and Chism, 1998). Therefore, we used rapid adhesion as a
method to enrich for keratinocyte stem cells. After four
successive cycles of growth in defined keratinocyte serum-
free medium (DKSFM) with supplements following rapid
attachment to ColIV plates, the morphology of these cells
resembled that of normal primary keratinocytes (Figure 2e),
and these cells continued to express GFP (Figure 2f). In
addition, consistent with their differentiation into a keratino-
cyte lineage, these cells coexpressed both Krt14, and its obli-
gate partner, Krt5 (Figure 2g). We successfully differentiated
two independent clones of iPSCs and obtained two lines of
iPSC-derived keratinocytes (iPSC-KCs) with similar efficiency.
Molecular characterization of iPSC-KCs
We further characterized iPSC-KCs on a molecular level. We
found that the expression of endogenous ESC markers (namely
Oct3/4, Sox2, and Nanog) and that of retrovirally encoded
Oct3/4 and Sox2 was completely silenced in iPSC-KC cultures
(Supplementary Figure S1b online, lane 6). However, residual
levels of the retrovirally encoded Klf4 and c-Myc were still
detectable. Importantly, iPSC-KCs expressed Krt14, as well as
endogenous c-Myc and Klf4, at levels comparable with those
of normal cultured keratinocytes (Supplementary Figure S1b
online, lane 5). The expression of Krt14 was further confirmed
by flow cytometric analysis, which revealed that the percen-
tage of Krt14-positive cells in iPSC-KC cultures (75%)
(Figure 2d) was similar to that in primary keratinocyte cultures
(86%) (Figure 2b). Furthermore, the silencing of endogenous
Nanog and Oct3/4 in iPSC-KC cultures (Supplementary
Figure S1b online, lane 6) confirms that our selection method
had eliminated undifferentiated iPSCs. We were able to
passage the established iPSC-KC lines for B40 days, and their
proliferation rate was similar to that observed for normal
primary mouse keratinocytes (Supplementary Figure S4 online).
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Figure 2. iPSC-KC cultures derived from differentiated EBs exhibit keratinocyte-like characteristics. (a–d): Undifferentiated iPSCs (panel a), primary
keratinocytes isolated from newborn ICR mice and cultured for 3 weeks (panel b), differentiated EBs (panel c), and iPSC-KCs (panel d) were analyzed
for the expression of Krt14 by flow cytometry. Enriched iPSC-KC cultures contained a similar proportion of Krt14-positive cells as primary cultured
keratinocytes. (e–g): iPSC-KCs (panel e) demonstrated a cobblestone morphology similar to primary keratinocytes and continued to express GFP (panel f).
Double labeling for Krt14 (green) and Krt5 (red) confirmed that the cells in panel e expressed keratinocyte markers (panel g). EB, embryoid body;
GFP, green fluorescent protein; iPSC-KC, iPSC-derived keratinocyte; Krt, keratin; PE, phycoerythrin. Bar¼100 mm.
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Differentiation of iPSC-KCs in response to calcium
Primary mouse keratinocytes can be induced to differentiate
and stratify in response to an increase in extracellular calcium
concentration in vitro (Yuspa et al., 1989). Therefore, we
assessed whether iPSC-KCs would respond in a similar
manner. We induced differentiation of iPSC-KCs by increasing
Ca2þ concentration in the culture medium from 0.02 to
0.35mM. In normal primary keratinocytes, such a shift
diminishes the expression of Krt14 and induces the expression
of differentiation markers, such as Krt1 and loricrin (Yuspa
et al., 1989). Similar to normal mouse keratinocytes, iPSC-KCs
stratified and began expressing Krt1 and loricrin when shifted
from low (Figure 3a, c, and e) to high calcium medium
(Figure 3b, d, and f). Importantly, iPSC-KCs did not express
Krt1 (Figure 3c) or loricrin (Figure 3e) in the low calcium
medium, thus confirming that iPSC-KCs can be maintained in
an undifferentiated state in vitro.
In vivo characterization of iPSC-KCs
To determine whether iPSC-KCs are multipotent, i.e.,
whether they exhibit the ability to regenerate normal skin
and its appendages, we performed an in vivo grafting
experiment as described in detail in the ‘‘Materials and
Methods’’ section. Undifferentiated iPSCs or iPSC-KCs were
mixed with freshly isolated dermal fibroblasts and trans-
planted into a silicon chamber that was implanted under-
neath the skin of nude mice as described previously (Lichti
et al., 2008). As a positive control, we also grafted primary
keratinocytes from ICR mice. Six weeks after grafting, the
grafts were removed and analyzed for the expression of Krt14
(expressed in the basal layer of the skin), Krt10 (expressed in
the suprabasal layers of the skin), GFP (expressed in iPSCs
and iPSC-KCs), Krt71 (previously known as Krt6irs1, which is
expressed in the inner root sheath of the hair follicle; Aoki
et al. (2001)), and adipophilin (a cytoplasmic lipid droplet-
binding protein expressed in sebaceous glands; Heid et al.
(1998)). Similar to primary keratinocytes (Figure 4a and
Figure 5a–e), iPSC-KCs gave rise to all epidermal layers,
as determined by their Krt14 and Krt10 staining pattern
(Figure 5l), including de novo hair follicles (Figures 4c and 5k
and n) and sebaceous glands (Figure 5k and o). As the
majority of iPSC-KC grafts were positive for GFP (Figures 4d
and 5m and o), we can conclude that the epidermis, hair
follicles, and sebaceous glands originated from iPSC-KCs.
Note the patches of GFP negative areas, which may have
arisen due to the loss of expression of the MSCV–IRES–GFP
retrovirus used to generate iPSCs. As others have shown, the
spontaneous silencing of integrated proviruses can occur in
many primary cell lines, including ESCs and iPSCs (Challita
and Kohn, 1994; Takahashi and Yamanaka, 2006; Okita
et al., 2007; Yu et al., 2007).
In contrast to iPSC-KCs, undifferentiated iPSCs consis-
tently formed poorly differentiated tumors positive for GFP
(Figure 5f, h, and j). The lack of GFP expression in the
epidermis established above the tumor (Figure 5g and h), as
well as the absence of hair follicles and sebaceous glands,
suggests that this epidermis is formed by the lateral migration
of keratinocytes from the host animal rather than the in vivo
differentiation of grafted iPSCs. These observations have
important implications as they document that the in vivo
environment of the graft is not sufficient to induce undiffer-
entiated iPSCs into a keratinocyte lineage. Therefore, before
iPSCs can be used for clinical applications, efficient methods
must be developed for the differentiation of iPSCs into
a keratinocyte lineage to avoid the risk of tumor formation.
At the time the grafts were removed for analysis (6 weeks
post-grafting), neither primary keratinocytes nor iPSC-KC-
reconstituted skin grafts exhibited signs of tumor formation.
DISCUSSION
The reprogramming of somatic cells into iPSCs provides an
attractive alternative to the use of ESCs for regenerative
medicine, as the therapeutic use of cells derived from a
patient’s own iPSCs would potentially avoid the complica-
tion of immune rejection. This is especially important
for keratinocytes, which express major histocompatibility
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Figure 3. iPSC-KCs differentiate in response to calcium. (a, b): Phase-contrast images of iPSCs-KCs cultured in DKSFM containing 0.02mM Ca2þ (low Ca2þ )
or 0.35mM Ca2þ (high Ca2þ ) for 2 days. Note that cells cultured in high Ca2þ medium flattened out and started to stratify (panel b). (c–f): The cells
were analyzed for the expression of Krt1 (red) and Krt14 (green) in low (panel c) and high Ca2þ medium (panel d), and Lor (green) and Krt14 (red) in low
(panel e) and high (panel f) Ca2þ medium. DKSFM, defined keratinocyte serum-free medium; GFP, green fluorescent protein; iPSC-KC, iPSC-derived
keratinocyte; Krt, keratin; Lor, loricrin. Bar¼ 100mm.
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complex class I molecules. Recently, investigators have
suggested that keratinocytes derived from human ESCs may
provide an important source of allogeneic keratinocytes
which could be used to reconstitute the skin of burn patients
and patients who suffer from devastating inherited skin
fragility syndromes (Guenou et al., 2009). This conclusion
was based on the finding that major histocompatibility
complex class I expression was extremely low in ESC-derived
keratinocytes grown both in culture and as skin equivalents
on immunocompromised mice (Guenou et al., 2009). A
major concern with this conclusion is that when ESC-derived
keratinocytes are used to reconstitute the skin in an
immunocompetent individual, which will eventually be
exposed to pathogens, this challenge will trigger the
expression of major histocompatibility complex class I
molecules by ESC-derived keratinocytes and will result in
immune rejection. An additional concern is that the low level
of major histocompatibility complex class I expression by
ESC-derived keratinocytes may render them subject to killing
by natural killer cells.
A major challenge in the derivation of any cell type,
including keratinocytes, from either ESCs or iPSCs is that only
a small subset of ESCs or iPSCs can be differentiated into the
cell type of interest, resulting in a highly heterogeneous cell
population along with the remaining undifferentiated ESCs
or iPSCs, which could cause tumor formation when these
cells are used for tissue regeneration in vivo. Indeed, the
differentiation of iPSC-derived EBs results in a low number of
Krt14-positive cells (25%) (Figure 2c), which is consistent
with the number of Krt14-positive cells obtained by other
groups during differentiation of ESC-derived EBs (Aberdam
et al., 2008; Metallo et al., 2008). The development of tumors
in the grafts of undifferentiated iPSCs (Figure 5f, h, and j)
further emphasizes the importance of developing efficient
methods for differentiating iPSCs and for eliminating un-
differentiated iPSCs from iPSC-KCs before transplantation.
Although antibodies against cell surface markers in combina-
tion with FACS can be used for isolation of pure hemato-
poietic stem cell populations (Civin and Loken, 1987; Uchida
et al., 1993; Bernstein et al., 1994), specific cell surface
markers have not been identified for keratinocyte stem cells.
As an alternative approach to enrich for iPSC-KC stem cells
and to eliminate undifferentiated iPSCs, we took advantage of
the previously reported ability of keratinocyte stem cells to
rapidly attach to ColIV-coated surfaces (Bickenbach and
Chism, 1998). After repeated cycles of rapid attachment on
ColIV plates and growth in the DKSFM medium, we were
able to eliminate undifferentiated iPSCs and obtain an
enriched population of multipotent keratinocyte stem cells
capable of regenerating both the skin and its appendages in
an in vivo model.
Although iPSC-KC stem cells were able to regenerate the
epidermis, hair follicles, and sebaceous glands in an in vivo
graft assay, it will be important to determine in future
experiments whether iPSC-KCs are stable in the long term.
As we used a retroviral approach to generate iPSCs, we
were unable to address the long-term survival and stability of
iPSC-KCs in our study. As others have shown, although the
retroviral constructs are silenced upon the generation of
iPSCs, the transgenic factors may be expressed at residual
Primary keratinocytes iPSC-KCs
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Figure 4. iPSC-KCs are able to regenerate skin and hair in vivo. (a) Primary keratinocytes or (c) iPSC-KCs were grafted with dermal cells isolated from
newborn ICR pups. Note de novo hair formation in both grafts. (b, d) Only iPSC-KCs (panel d), but not wild-type primary keratinocytes (panel b), regenerated a
skin graft positive for GFP, confirming its iPSC-KC origin. GFP, green fluorescent protein; iPSC-KC, iPSC-derived keratinocyte. Bar¼1mm.
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levels (Supplementary Figure S1b online) (Takahashi and
Yamanaka, 2006; Okita et al., 2007; Yu et al., 2007) and are
spontaneously reactivated (Hanna et al., 2007; Okita et al.,
2007), which can result in tumor formation in vivo. To
address the long-term stability of iPSC-KCs in the future, it
will be necessary to generate iPSCs using transgene-free
protocols.
In conclusion, our observations have important impli-
cations for the eventual use of iPSCs for the correction of
inherited skin diseases in humans. This is especially true for
epidermolysis bullosa, a group of rare and incurable inherited
skin blistering diseases that result in severe blistering and
scaring that can be lethal. To date, there has been only one
successful report describing the use of genetically modified
keratinocyte stem cells to correct epidermolysis bullosa
(Mavilio et al., 2006). De Luca et al. used a murine leukemia
virus-derived retroviral vector to introduce laminin 5 into
keratinocytes isolated from a patient with junctional epider-
molysis bullosa (Mavilio et al., 2006). However, because of
the fact that several X-severe combined immunodeficient
(SCID) patients developed leukemia when treated with
similar retroviral vectors, De Luca’s clinical trial has been
placed on hold (reviewed in the study by De Luca et al.
(2009)). Thus, the safety concerns arising from the random
integration of retroviral- or lentiviral-based vectors require
the consideration of alternative approaches to treat these
diseases. Another factor that must be taken into consideration
with epidermolysis bullosa patients, who are constantly
undergoing wound repair as a result of blistering, is the
exhaustion of their keratinocyte stem cells. This was
especially apparent in the case of De Luca’s patient, who
had exhausted most of his keratinocyte stem cells, except for
those in the palms (Mavilio et al., 2006). The generation of
iPSCs from dermal fibroblasts of epidermolysis bullosa
patients would solve this problem. Once iPSCs are generated
from an epidermolysis bullosa patient, they could be
expanded, genetically corrected, frozen, and used indefi-
nitely to generate keratinocytes to be returned to the same
patient as autografts. Although the ultimate goal is the use of
iPSCs in the treatment of human diseases, extensive research
is still required with preclinical models before this technology
can be introduced into the clinic. For this reason, our
methodology for the differentiation of mouse iPSCs into
multipotent keratinocytes is of particular importance as it will
now allow an assessment of the therapeutic applicability of
iPSCs in the treatment of inherited skin disorders, using
genetically engineered mouse models that mimic these
diseases (Arin et al., 2001; Cao et al., 2001).
MATERIALS AND METHODS
Retroviral constructs and generation of iPSCs
Murine iPSCs were generated by transducing 3 105 freshly isolated
ICR (Hsd: ICR (CD-1)) mouse (Harlan Laboratories, Indianapolis, IN)
dermal fibroblasts with four retroviruses encoding murine Oct3/4,
Klf4, Sox-2, and c-Myc as originally reported by Yamanaka (in the
study by Takahashi and Yamanaka (2006)). Culturing transduced
fibroblasts under ESC conditions in the presence of 0.5mM valproic
acid (Huangfu et al., 2008) (Sigma-Aldrich, St Louis, MO) resulted in
the generation of B2,200 ESC-like colonies. Mouse Oct3/4, Klf4,
and Sox2 pMxs retroviral vectors were obtained from Addgene
(Cambridge, MA), whereas the c-Myc construct was generated
by cloning mouse c-Myc cDNA into an MSCV–IRES–GFP vector
(pMIG, Addgene).
Cell culture
Mouse CJ7 ESCs and iPSCs were maintained on mouse embryonic
fibroblasts treated with mitomycin C (Sigma-Aldrich) in ESC medium
with leukemia inhibitory factor (LIF) (Millipore, Billerica, MA) as
described previously (Evans and Kaufman, 1981; Zhou et al., 2010).
For differentiation of iPSCs into a keratinocytes lineage (Supple-
mentary Figure S3 online), 100 EBs were formed from 5 104 mouse
iPSCs on a Petri dish in ESC medium without LIF (ESC-no-LIF
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Figure 5. iPSC-KCs are multipotent in vivo. Consecutive sections of skin
grafts regenerated with (a–e) wild-type primary keratinocytes, undifferentiated
(f–j) iPSCs, or (k–o) iPSC-KCs were analyzed for the expression of markers
specific for the epidermis, hair follicles, and sebaceous glands at 6 weeks
post-grafting. (Panels a, f, k) H&E; (panels b, g, l) Krt14 (red) and Krt10 (green);
(panels c, h, m) Krt14 (red) and GFP (green); (panels d, i, n) Krt14 (red)
and Krt71 (green); (panels e, j, o) adipophilin (Adipo, red) and GFP (green).
Wild-type primary keratinocytes (panels a–e) and iPSC-KCs (panels k–o)
were capable of regenerating the epidermis, hair follicles, and sebaceous
glands. Note the formation of a tumor-like mass in the graft containing
undifferentiated iPSCs (panels f, h, j). These images are representative of two
independent grafting experiments performed with two different iPSC-KC lines
and two grafts per condition. GFP, green fluorescent protein; H&E,
hematoxylin and eosin; iPSC, induced pluripotent stem cell; iPSC-KC,
iPSC-derived keratinocyte; Krt, keratin. Bar¼ 100mm.
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medium). After 2 days, 30 EBs were transferred to a new Petri dish
with the ESC-no-LIF medium containing 1mM retinoic acid and
maintained in suspension culture for three more days. Differentiated
EBs were then transferred onto a ColIV (Sigma-Aldrich)-coated
100mm tissue culture plate with the ESC-no-LIF medium containing
25 ngml1 mouse recombinant bone-morphogenetic protein-4
(R&D Systems, Minneapolis, MN), and B25 EBs were able to
adhere to the surface, an efficiency of B80%. After 3 days in the
bone-morphogenetic protein-4-containing medium, the plated EBs
were switched to DKSFM (Invitrogen, Carlsbad, CA), cultured for six
more days, and passaged onto a fresh ColIV plate in DKSFM. At this
point, we removed EB remnants by vacuum aspiration and enriched
the culture for keratinocyte stem cells by exploiting the rapid
adherence properties of Krt14-positive keratinocyte stem cells to
ColIV (Bickenbach and Chism, 1998). In particular, iPSC-KCs
were detached from the plate with trypsin (0.25% trypsin-EDTA,
Invitrogen), trypsin was inactivated by addition of DKSFM contain-
ing 10% chelexed fetal bovine serum, and iPSC-KCs were selected
by rapid attachment to ColIV plates for 15minutes at room
temperature in DKSFM. Nonadherent cells were rinsed off and
discarded, whereas rapidly attached cells were cultured in DKSFM
on ColIV plates for four passages (B3 weeks). At this point, cells
were analyzed in vitro and in vivo.
Primary keratinocytes and iPSC-KCs were cultured on ColIV
plates in DKSFM with supplements and seeded at 3 104 cells
per cm2 with each passage.
Teratoma formation
Mouse iPSCs (5 105 cells) were injected subcutaneously into
the flank of 6-week-old Foxn1nu nude mice (The Jackson Laboratory,
Bar Harbor, ME). The animals developed tumors within 1 month
after injection.
Immunofluorescence analysis
Cells were fixed in cold methanol. Tissues were fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned and stained
with hematoxylin and eosin. Double-immunofluorescence labeling
was performed as described previously (Wojcik et al., 2001). The
primary antibodies used were against Krt1 (Yuspa et al., 1989),
Krt10 (Yuspa et al., 1989), Krt14 (Yuspa et al., 1989), Krt5 (Yuspa
et al., 1989), loricrin (Mehrel et al., 1990), Krt8/Krt18 (Progen
Scientific, Mexborough, South Yorkshire, UK ), p63 (Santa Cruz
Biotechnology, Santa Cruz, CA), Nanog (Chemicon, Temecula, CA),
Krt71 (Aoki et al., 2001), adipophilin (Fitzgerald Industries
International, Concord, MA), GFP (Abcam, Cambridge, MA),
cytokeratin Endo-A (TROMA-1), and adult skeletal muscle myosin
heavy chain (A4.1025) (Developmental Studies Hybridoma
Bank, Iowa City, IA). The secondary antibody conjugates used were
Alexa-conjugated fluorochromes 594 and 488 (Molecular Probes,
Eugene, OR).
Reverse transcription-PCR
Total RNA was extracted from cells using the RNeasy Mini kit
(Qiagen, Valencia, CA), and cDNA was synthesized from 2mg of
RNA and 100ng random primers using SuperScript III Reverse
Transcriptase kit (Invitrogen). PCRs were conducted using Taq
Gold (Applied Biosystems, Foster City, CA) with 1ml of cDNA for
30 cycles. The primers used to detect the expression of trans-
genic factors were Oct3/4 forward/reverse: TGTGGTGGTACGGGA
AATCAC/GCTCCTGCCTGGCCCTCAG (amplicon—343bp); Sox2
forward/reverse: TGTGGTGGTACGGGAAATCAC/CTGTTCTTCTG
GTTGCCG (amplicon—199bp); Klf4 forward/reverse: GTGTGGTG
GTACGGGAAATCAC/CGTTGAACTCCTCGGTCTCCC (amplicon—
369bp); c-Myc forward/reverse: CACAAACTCGAACAGCTTCG/
CATATAGACAAACGCACACCGGC (amplicon—150bp). The primers
used to detect the expression of endogenous Nanog, Oct3/4, Klf4,
Sox2, and c-Myc were from the study by Takahashi and Yamanaka
(2006), Krt14 was from the study by Kobayashi et al. (2009), and
GAPDH was CGTCCCGTAGACAAAATGGT (forward) and TCTCCAT
GGTGGTGAAGACA (reverse) with amplicon size of 350bp.
Flow cytometry
Cells were processed for flow cytometry as described previously
(Aberdam et al., 2008). The primary antibody used was sheep anti-
Krt14 (Roop et al., 1984). Control samples were included using
isotype-specific antibody or no primary antibody. Goat anti-sheep
phycoerythrin-conjugated antibody (Abcam) was used as a second-
ary antibody. Fluorescence was detected using a Cytomics FC 500
cytometer (Beckman Coulter, Brea, CA).
In vivo grafting model
The in vivo grafting experiment was performed as described
previously (Lichti et al., 2008). Approximately 1 106 mouse
primary keratinocytes, undifferentiated iPSCs, or iPSC-KCs were
mixed in a 1:1 ratio with dermal fibroblasts freshly isolated from
newborn ICR mice (same background as iPSCs) and transferred into
the silicon graft chambers that were implanted underneath the skin
of athymic nude (Foxn1nu) mouse. After 2 weeks, the graft chambers
were removed, and 4 weeks later, the grafts were harvested, fixed,
and sectioned. The sections were processed for either hematoxylin
and eosin staining or immunofluorescence analysis as described
above.
All experiments were performed in accordance with the guide-
lines developed by the UCD (University of Colorado Denver)
Institutional Animal Care and Use Committee and with approval
from the UCD Ethics Committee.
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